Teva Pharmaceutical (TEVA) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Teva Pharmaceutical (TEVA)

34.43

+1.60 (4.87%)

as of Jun 4, 2026, 8:00:00 pm Market Open.

69 watching

Investor Insights

Jun 4, 2026, 12:00 am

This summary was created by AI, based on 2 opinions in the last 12 months.

Teva Pharmaceutical, traded under the symbol TEVA-N, has shown significant improvement, gaining 264% since the new CEO took office in January 2023, suggesting a robust turnaround for the company. After experiencing a rough period post-2002, recent positive financial results indicate that the company's performance is on the upswing. The headquarters in Israel underline its position as a large-cap player in the pharmaceutical industry. Under the current market conditions, Teva is ranked #1 in its ADR/CDR universe, benefiting from a rotation towards drug stocks. Its stock broke through the $21 barrier in September, continuing its upward trend with strong accumulation for the past six months, despite not currently offering a dividend. Analysts are optimistic about its prospects, projecting a price target of $34.50.

Consensus

Positive

Valuation

Undervalued

Similar

Pfeizer, PFE

BUY

The best company to own in the generics drug area.

TOP PICK

Sitting by its all-time high even in this poor market. Largest generic drug manufacturer in the world. A major beneficiary of an economic slowdown because people will switch from branded products to generics. Major beneficiary of drugs coming off patent.

PAST TOP PICK

(A Top Pick July 25/06. Up 42%.) Still a Buy. The biggest generic drug manufacturer in the world.

BUY

An Israeli generics pharmaceutical company. At these levels, it is a very interesting stock.

TOP PICK

World's largest generic drug manufacturer. Has gone from being a growth stock to a value stock. A lot more patented drugs will be coming off in 2007 and 2008.

BUY

World’s largest generic drug manufacturer. Also have their own branded drug division. Made some acquisitions and is going through some digestion, but a year from now the stock should be significantly higher.

BUY

Generic pharmaceutical company. Very well run. Lots of cash.

BUY

World’s largest generic drug manufacturer. A value stock. Has a great pipeline of new drugs coming out in the next few years, both generic and its own proprietary drugs. Pfizer’s (PFE-N) Lipitor drug does not come off patent until 2011.

BUY

World’s largest generic drug manufacturer with most sales in North America. Reported great earnings, but stock has acted poorly lately because next year’s growth is not going to be as big. Good price.

BUY

Generic drugs. Trades and about 16 X earnings. Has a lot of cash on its balance sheet. There is a lot of competition in the generic sector still expects there will be mergers. It should continue to do well.

TOP PICK

World's largest generic drug manufacturer. Gone from being a growth stock to a value stock. Merck and Pfizer have come out with their own generics when their drugs came off patent. Based in Israel. The drop in price gives a good opportunity.

BUY

Largest generic drug manufacturer in the world. Likes long-term outlook for generics. Emerging markets have come off which affected the stock. Bit of a tumult on drugs coming off patent with original patent owners issuing drugs for less than generics. A temporary phenomena and this company will again be on top.

WAIT

In the top 2 of the world's generic drug manufacturers. Interesting dynamics going on in the healthcare sector. When the patent came off Zocor, Merck (MRK-N) lowered their price below the generic price. This was a first but other companies could follow this tactic so, he is staying on the sidelines. Recently sold his holdings.

PAST TOP PICK

(A Top Pick May 30/05. Up 4%.) Trading at a lower multiple and is a bigger stronger company than it was a year ago. Has more new business going for them. Still attractive.

BUY

Israeli based pharmaceutical company. Largest generic drug manufacturer in the world. Most recent quarter was a little lighter than expected. Acquired a US company made the numbers are little bit light. Good opportunity to buy.

Showing 226 to 240 of 274 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Darren Sissons

Campbell Lee & Ross

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Teva Pharmaceutical (TEVA)